The Global Fund, one of the main purchasers of generic antiretroviral (ARV) medicines for HIV patients in low- and middle-income countries, has dismissed concerns that the limited number of manufacturers tapped to supply these drugs could result in immediate or future shortages. Fund officials said systems are in place to forecast demand, deal with any supply disruptions and increase production to meet future need.
In the second half of 2015, through programs supported by The Global Fund, another 641,000 people were put on antiretroviral treatment (ART) for HIV, bringing the total to date to 9.2 million, a 7.5% increase over mid-2015 results and a 14.5% increase over the numbers a year ago.
In the first half of 2015, through programs supported by The Global Fund, another 500,000 people were put on antiretroviral treatment for HIV, bringing the total to date to 8.6 million, a 7% increase over end-2014 results.
Sustainability was a prominent theme in the November report of the Grant Approvals Committee to the Board. Ten of the 22 grants recommended for approval had already taken some steps towards sustainability or included measures in their proposed programs. Three of the 10 grants were from low income countries.